Pharm Week 2: Comprehensive Study Guide on Anti-Infective Pharmacology and Immunotherapy

Principles of Anti-Infective Therapy

• Anti-infective agents are medications designed to target foreign organisms (including bacteria, viruses, fungi, and parasites) that have invaded and infected a human host.

• Therapeutic actions of anti-infective agents:

  • Bacteriostatic: Inhibits the growth and reproduction of bacteria without directly killing them.

  • Bactericidal: Directly kills the bacteria.

• Primary Clinical Goal: To reduce the population of the infectious organism to a level low enough for the host's intact immune response to effectively eliminate the remaining infection.

Antimicrobial Resistance

• Resistance refers to the ability of an infectious pathogen to survive and multiply despite exposure to an anti-infective agent.

• Types of Resistance:

  • Natural Resistance: Inherent resistance present in an organism prior to any anti-infective exposure, attributable to its structural characteristics or baseline metabolic mechanisms.

  • Acquired Resistance: Resistance that develops over time after exposure to antimicrobial agents.

• Drivers of Acquired Resistance:

  • Overuse of broad-spectrum antibiotics.

  • Inappropriate or inaccurate prescribing practices.

  • Patient non-compliance, specifically failing to complete the full prescribed course of treatment.

  • Indiscriminate use of antibiotic agents for viral infections.

• Key Nursing Implications for Antimicrobial Stewardship:

  • Obtain diagnostic cultures prior to initiating the first dose of antibiotic therapy.

  • Practice and promote rigorous anti-infective stewardship (administer anti-infectives only when clinically indicated).

  • Educate patients to complete their entire antibiotic prescription, take doses exactly as prescribed, and never share antibiotics with others.

Diagnostic Culture and Sensitivity Testing

• Culture (Data Collection):

  • Purpose: Identifies the specific organism or pathogen causing the infection.

  • Clinical Action: Samples of body fluids or tissue swabs are collected prior to antibiotic administration.

• Sensitivity (Searching for Correct Treatment):

  • Purpose: Determines which specific anti-infective medication will effectively kill or inhibit the identified pathogen.

  • Clinical Action: Lab tests measure the susceptibility of the isolated organism to various pharmacological agents.

• Anti-Infective Application Protocols:

  • Systemic Infection Treatment: Guided by pathogen identification and sensitivity profiling.

  • Combination Therapy: Utilizing multiple anti-infective classes to target resistant organisms or produce synergistic effects.

  • Prophylaxis: Administration of anti-infectives prior to high-risk exposure or surgical procedures to prevent initial colonization.

Systemic Adverse Reactions of Anti-Infective Agents

• Kidney Damage (Nephrotoxicity): Renal tissue injury impacting filtration and drug excretion.

• Gastrointestinal Toxicity: Ranging from severe nausea and vomiting to pseudomembranous colitis.

• Neurotoxicity: Manifesting as central or peripheral nervous system disturbances.

• Hypersensitivity Reactions: Ranging from mild cutaneous rashes and urticaria to life-threatening anaphylaxis.

• Superinfections: Secondary infections occurring when normal host flora is destroyed (e.g., Clostridioides difficile, oral or vaginal candidiasis).

Antibiotic Classification and Bacterial Identification

• Bacteria are classified based on Gram staining, oxygen requirement, and cell wall structure:

  • Gram-Positive Organisms: Possess a thick peptidoglycan cell wall; commonly cause respiratory tract and soft tissue infections.

  • Gram-Negative Organisms: Possess an outer membrane cell wall structure; commonly cause gastrointestinal (GI) and genitourinary (GU) tract infections.

  • Aerobic Organisms: Require oxygen for metabolic survival.

  • Anaerobic Organisms: Function and survive in environments devoid of oxygen.

Aminoglycosides

• Prototype Drug: Gentamicin

• Indications: Used to treat severe infections caused by aerobic Gram-negative bacteria (e.g., Escherichia coli).

• Mechanism of Action (MOA): Binds to the $30\text{S}$ ribosomal subunit to inhibit protein synthesis; produces a bactericidal effect.

• Routes of Administration: Intramuscular (IM) or Intravenous (IV).

• Adverse Effects:

  • Ototoxicity (damage to auditory and vestibular systems).

  • Nephrotoxicity (damage to renal tubules).

  • Neurotoxicity.

  • Gastrointestinal disturbances.

  • Headache.

• Contraindications:

  • Known hypersensitivity to aminoglycosides.

  • Pregnancy.

  • Pre-existing kidney disease.

  • Pre-existing hearing impairment.

• Key Drug Interactions:

  • Cephalosporins: Concurrent administration significantly increases the risk of nephrotoxicity. Monitor blood urea nitrogen (BUN) and serum creatinine levels closely.

• Therapeutic Drug Monitoring (Peak and Trough):

  • Peak Level: Represents the highest drug concentration in the patient's bloodstream. Drawn approximately $1$ to $1.5\,\text{hours}$ after administration (depending on clinical protocol and infusion completion).

  • Trough Level: Represents the lowest drug concentration in the patient's bloodstream. Drawn precisely $30\,\text{minutes}$ prior to administering the next scheduled dose.

• Nursing Considerations:

  • Always obtain culture and sensitivity tests prior to administering the first dose.

  • Screen for patient allergy history.

  • Monitor strict urine output and baseline/ongoing kidney function (BUN and creatinine).

  • Assess hearing capability and balance for signs of vestibular or auditory toxicity.

  • Draw peak and trough blood levels at appropriate time intervals.

  • Encourage adequate hydration to maintain urinary flow.

• Patient Teaching Points:

  • Complete the full course of prescribed therapy.

  • Immediately report ringing in the ears (tinnitus), hearing loss or changes, dizziness, or a significant decrease in urine output.

• Developmental Considerations:

  • Infants: Exceptionally high risk for ototoxicity.

  • Pediatrics: Possess immature renal function resulting in unpredictable drug clearance.

  • Older Adults: Age-related decline in renal function increases toxicity risk; dosage must be calculated based on renal clearance, and serum levels must be monitored closely.

Carbapenems

• Prototype: Class only

• Indications: Reserved for serious or life-threatening bacterial infections, such as sepsis, multidrug-resistant infections, complicated urinary tract infections (UTIs), and complex intra-abdominal infections.

• Mechanism of Action (MOA): Inhibits bacterial cell wall synthesis; broad-spectrum bactericidal activity.

• Routes of Administration: Intravenous (IV) or Intramuscular (IM).

• Adverse Effects:

  • Seizures and neurotoxicity.

  • Clostridioides difficile (C. diff) infection.

  • Bone marrow suppression.

  • Gastrointestinal disturbances and headache.

  • Cutaneous rash and severe hypersensitivity reactions.

  • Superinfections with prolonged use.

• Contraindications:

  • Known severe allergy to beta-lactam antibiotics (penicillins or cephalosporins).

  • Pregnancy.

• Key Drug Interactions:

  • Valproic Acid: Carbapenems decrease serum levels of valproic acid, leading to an increased risk of breakthrough seizures.

  • Imipenem: Specific combination regimens with imipenem can independently increase seizure risks.

• Mnemonic for Carbapenems (FINAL):

  • F: For resistant infections: Used when other antibiotics fail; avoid overuse to prevent resistance.

  • I: IV or IM route: IV mainly in hospitalized inpatients (no oral options available).

  • N: Neuro risk for seizures (especially imipenem); assess baseline seizure history.

  • A: Allergy potential: Due to its beta-lactam structure, cross-reactivity with PCN/cephalosporins exists (ask about allergy).

  • L: Labs for kidney function: Monitor creatinine, BUN, and intake & output (I&O).

• Nursing Considerations:

  • Obtain culture and sensitivity prior to initiating therapy.

  • Carefully assess history of beta-lactam allergies and seizure disorders.

  • Monitor bowel function and frequency.

  • Monitor laboratory renal markers (BUN, serum creatinine).

• Patient Teaching Points:

  • Complete the entire prescribed regimen.

  • Report severe diarrhea, watery stool, or bloody stools immediately.

• Developmental Considerations:

  • Pediatrics: Elevated baseline seizure risk.

  • Older Adults: Assess renal clearance parameters (BUN, creatinine, eGFR); require age- and renal-adjusted dosing; monitor mental status, seizure activity, hydration, and bowel habits.

Cephalosporins

• Mnemonic for Cephalosporin Generations:

  • $1\text{st}$ Generation: Starts with "cefa" sounds (cefazolin, cephalexin, cefadroxil; Exception: cefaclor is a $2\text{nd}$ generation agent).

  • $2\text{nd}$ Generation: "$2$ furry foxes tan faces like pros" (cefuroxime, cefoxitin, cefotetan, cefaclor, cefprozil).

  • $3\text{rd}$ Generation: "$3$ po'docs fixing dinner got tazed for late taxes" (ceftriaxone, cefpodoxime, cefixime, cefdinir, ceftazidime, cefotaxime).

  • $4\text{th}$ Generation: Contains root word 'pi' (cefepime).

  • $5\text{th}$ Generation: Contains root word 'ol' (ceftolozane, ceftaroline).

• Trends Across Cephalosporin Generations ($1\text{st} \rightarrow 5\text{th}$):

  1. Increasing activity against Gram-negative bacteria.

  2. Increasing ability to penetrate the blood-brain barrier (BBB) (especially $3\text{rd}$ generation and beyond).

  3. Increasing resistance to destruction by $\beta$-lactamase enzymes.

• Mechanism of Action (MOA): Inhibits cell wall synthesis; exhibits bacteriostatic or bactericidal action depending on drug concentration and generation.

• Routes of Administration: Oral (PO), Intramuscular (IM), Intravenous (IV).

• Adverse Effects:

  • Gastrointestinal manifestations (nausea, severe diarrhea).

  • Cutaneous rash and allergic reactions.

  • Pseudomembranous colitis (C. difficile).

  • Nephrotoxicity.

  • Risk of hemorrhage (specifically Cefotetan, due to interference with vitamin K metabolism).

  • Disulfiram-like ethanol reaction (specifically Cefotetan).

  • Infusion-site thrombophlebitis with IV administration.

• Contraindications:

  • Known allergy to beta-lactam antibiotics.

  • Pre-existing renal impairment.

  • Ethanol consumption (strictly contraindicated with Cefotetan).

• Key Drug Interactions:

  • Aminoglycosides: Increased risk of severe nephrotoxicity.

  • IV Calcium Solutions: Causes fatal precipitation and organ damage in neonates (specifically Ceftriaxone).

  • Warfarin: Potentiates anticoagulant effects, increasing bleeding risk.

• Nursing Considerations:

  • Obtain culture prior to the first dose.

  • Evaluate PCN cross-allergy risks.

  • Monitor bowel patterns, renal function labs, prothrombin time (PT/INR), and signs of bleeding.

  • Dilute IV infusions as directed and administer slowly to prevent phlebitis.

• Mnemonic for Cephalosporin Safety (CEPHAL):

  • C: Creatinine/BUN: Monitor kidneys; can be nephrotoxic.

  • E: ETOH intolerance: No alcohol; risk of disulfiram-like reaction (avoid alcohol during and for $72\,\text{hours}$ post-treatment).

  • P: Pseudomembranous colitis: Watch for C. diff (watery diarrhea, fever).

  • H: Hypersensitivity: Ask about PCN allergy (cross-sensitivity); risk of rash or anaphylaxis.

  • A: Administration: IV $\rightarrow$ phlebitis risk; IM $\rightarrow$ inject into a large muscle mass.

  • L: Lower prothrombin: Some agents interfere with vitamin K, causing potential bleeding; monitor PT/INR.

• Comparative Analysis of Representative Cephalosporin Agents:

  • Cephalexin ($1\text{st}$ Generation):

  • Route: PO (most common); occasionally IV/IM.

  • Indications: Skin/soft tissue infections, pediatric otitis media.

  • Spectrum: Narrower spectrum—primarily Gram-positive organisms.

  • Adverse Effects: GI upset (N/V/D), C. diff risk, rash, hypersensitivity, PCN cross-reactivity, high-dose seizures.

  • Nursing: Check PCN allergy, monitor rash/diarrhea/superinfections, renal dose adjustment required, administer with food.

  • Cefuroxime ($2\text{nd}$ Generation):

  • Route: PO, IV, or IM.

  • Indications: Respiratory infections (bronchitis, pneumonia), otitis media, skin infections.

  • Spectrum: Broader Gram-negative respiratory coverage compared to $1\text{st}$ generation.

  • Adverse Effects: Standard class adverse effects; disulfiram-like reaction with alcohol.

  • Nursing: Screen for allergy, monitor renal labs and diarrhea, reinforce therapy adherence, administer with food.

  • Ceftriaxone ($3\text{rd}$ Generation):

  • Route: IV or IM only.

  • Indications: Severe Gram-negative infections, bacterial meningitis, gonorrhea, severe pneumonia; excellent CNS penetration.

  • Distinguishing Features: Once-daily dosing; excreted via biliary tract (requires less renal dosage adjustment).

  • Adverse Effects: Class adverse effects plus biliary sludging (especially in neonates); avoid in severe hyperbilirubinemia.

  • Nursing: Evaluate allergy history; avoid in neonates with hyperbilirubinemia; do not mix or co-infuse with calcium solutions; monitor liver and renal function.

• Developmental Considerations:

  • Infants: Completely avoid Ceftriaxone in neonates due to risk of biliary sludging and calcium-precipitation organ toxicity.

  • Older Adults: Require renal dosage adjustments; monitor closely for secondary C. diff infections.

Fluoroquinolones

• Prototype Drug: Levofloxacin

• Indications: Severe bacterial infections, complicated urinary tract infections, and post-exposure prophylaxis for anthrax.

• Mechanism of Action (MOA): Inhibits essential bacterial DNA enzymes (DNA gyrase/topoisomerase); bactericidal.

• Routes of Administration: Oral (PO) and Intravenous (IV).

  • IV Administration Rules: Infuse slowly over a minimum of $60\,\text{minutes}$; highly incompatible with other medications in IV solutions and tubing.

• Adverse Effects:

  • GI manifestations: Nausea, vomiting, diarrhea.

  • Achilles Tendon Rupture: Elevated risk in older adults and patients co-prescribed systemic glucocorticoids.

  • CNS effects: Dizziness, severe headache, seizures, increased intracranial pressure, suicidal ideation.

  • Photosensitivity.

  • Hepatotoxicity.

  • C. difficile superinfection.

• Contraindications:

  • Active tendon pain or inflammation.

  • Myasthenia gravis (may exacerbate muscle weakness).

  • Caution: Pregnancy, pediatrics under $18\,\text{years}$, renal impairment, seizure disorders, GI disease.

• Key Drug Interactions:

  • Sucralfate and Antacids: Significantly decrease fluoroquinolone absorption.

  • Warfarin: Potentiates anticoagulant effects, increasing INR and bleeding risk.

  • Corticosteroids: Markedly increases the risk of tendon rupture.

  • Oral Antidiabetic Drugs: Increases risk of hypoglycemia.

  • Erythromycin: Increases risk for severe or fatal cardiac dysrhythmias.

• Nursing Considerations:

  • Assess for GI distress and monitor for localized tendon pain or swelling.

  • Patient Teaching:

  • Avoid excess caffeine intake.

  • Use sunscreen and protective clothing; avoid direct UV light.

  • Administer antacids or sucralfate $2\,\text{hours}$ after or $6\,\text{hours}$ before levofloxacin.

  • Maintain fluid intake of $1500\text{--}2000\,\text{mL/day}$.

  • Immediately report any tendon pain, tenderness, or swelling to the provider.

• Developmental Considerations:

  • Pediatrics: Generally avoided in children under $18\,\text{years}$ of age due to the risk of arthropathy and joint cartilage damage.

  • Older Adults: Markedly increased risk of Achilles tendon rupture, especially when combined with corticosteroid therapy.

Penicillins

• Broad-Spectrum Penicillin Prototype: Amoxicillin

  • Indications: Broad-spectrum coverage for common respiratory, ear, throat, and urinary tract infections.

  • MOA: Inhibits bacterial cell wall synthesis; bactericidal.

  • Routes: PO, IM, IV. Administer oral forms at the beginning of meals to optimize absorption and minimize GI distress.

  • Adverse Effects: GI distress (N/V/D); superinfections (Candida albicans, rarely C. diff).

  • Contraindications: Known allergy to beta-lactam antibiotics; hypersensitivity to procaine or benzathine additives.

  • Drug Interactions:

  • Probenecid: Blocks renal excretion, increasing serum penicillin levels.

  • Bacteriostatic Antibiotics: Antagonize the bactericidal activity of penicillin.

  • Oral Contraceptives: Decreases contraceptive efficacy.

  • Nursing Considerations:

  • Monitor patients closely for $30\,\text{minutes}$ following an IV dose for signs of anaphylaxis.

  • Assess history of allergies, monitor for diarrhea, bloody stools, or candidal infections.

  • Patient Teaching: Report watery/bloody stools or signs of oral/vaginal candidiasis immediately.

• Extended-Spectrum Penicillin Prototype: Piperacillin

  • Indications: Moderate-to-severe systemic infections including sepsis, hospital-acquired pneumonia, and Pseudomonas aeruginosa infections.

  • MOA: Inhibits cell wall synthesis; bactericidal.

  • Route: IV only.

  • Adverse Effects: Nephrotoxicity, systemic electrolyte imbalances, thrombocytopenia.

  • Contraindications: Known beta-lactam allergy. Caution in renal impairment, asthma/allergies, or heart failure (due to sodium load).

  • Drug Interactions: Probenecid (increases levels), bacteriostatic drugs (decrease efficacy), oral contraceptives (decreases efficacy).

  • Nursing Considerations: Monitor WBC counts, renal function (BUN, creatinine, eGFR), serum electrolytes ($Na^+$ and $K^+$), and monitor for C. diff.

• Penicillin Resistance Mechanisms:

  • Prolonged use of penicillins has driven bacterial evolution, leading organisms to synthesize the enzyme penicillinase (a specific $\beta$-lactamase) which cleaves the beta-lactam ring and inactivates the drug.

• Developmental Considerations:

  • Pediatrics: Dose piperacillin based strictly on weight; closely monitor renal function.

  • Older Adults: Adjust dosages for age-related renal clearance declines; monitor closely for C. diff, bleeding, electrolyte disturbances, and hypersensitivity reactions.

Sulfonamides

• Prototype Drug: Trimethoprim-Sulfamethoxazole (TMP-SMX)

• Indications: Combination therapy for UTIs, pneumonia, bronchitis, and pediatric otitis media.

• Mechanism of Action (MOA): Blocks bacterial folic acid synthesis; bacteriostatic.

• Routes of Administration: Oral (PO) or Intravenous (IV).

• Adverse Effects:

  • Gastrointestinal distress.

  • Blood cell deficiencies (leukopenia, anemia, thrombocytopenia).

  • Superinfections.

  • Stevens-Johnson Syndrome (SJS) (severe cutaneous hyper-reactivity).

  • Kernicterus (bilirubin accumulation in the brain of neonates).

• Contraindications:

  • Pregnancy and breastfeeding.

  • Megaloblastic anemia due to folate deficiency.

  • Infants under $2\,\text{months}$ of age.

  • Streptococcal pharyngitis.

  • Hyperkalemia or impaired renal creatinine clearance.

  • Caution: Impaired hepatic/renal function, bone marrow suppression, or sulfite sensitivity.

• Key Drug Interactions:

  • Alcohol: Induces a disulfiram-like toxicity reaction.

  • Warfarin: Increases risk of bleeding due to potentiated anticoagulation.

  • Methotrexate: Increases risk of bone marrow immunosuppression.

  • Oral Contraceptives: Reduces contraceptive efficacy.

• Nursing Considerations:

  • Assess for skin rash, hives, or severe diarrhea.

  • Encourage high fluid intake ($1200\text{--}1500\,\text{mL/day}$) to prevent crystalluria.

  • Track daily intake and output (I&O).

  • Monitor periodic Complete Blood Count (CBC) and urinalysis.

• Patient Teaching Points:

  • Take oral doses with food.

  • Immediately report rash, hives, watery diarrhea, mouth soreness, vaginal burning, fatigue, pallor, or unusual bruising/bleeding.

• Developmental Considerations:

  • Infants: Absolutely contraindicated under $2\,\text{months}$ due to kernicterus risk.

  • Pediatrics: Avoid in patients at risk for hemolytic anemia (e.g., G6PD deficiency).

  • Pregnancy/Lactation: Strictly contraindicated.

  • Older Adults: Elevated incidence of severe Stevens-Johnson syndrome and hematologic dyscrasias.

Tetracyclines

• Prototype Drug: Tetracycline

• Indications: First-choice therapy for Chlamydia, Mycoplasma infections, syphilis, tetanus, cholera, anthrax, and acne vulgaris.

• Mechanism of Action (MOA): Inhibits bacterial protein synthesis by binding to ribosomal subunits; bacteriostatic.

• Routes of Administration: PO (preferred). IM and IV routes are reserved exclusively for situations where PO is not tolerated.

• Adverse Effects:

  • GI toxicity.

  • Permanent discoloration of teeth in fetuses and young children.

  • Hepatotoxicity.

  • Superinfections (such as C. diff colitis).

  • Photosensitivity.

  • Suppression of long-bone growth in infants.

• Contraindications:

  • Pregnancy or breastfeeding.

  • Children under $8\,\text{years}$ of age.

  • Exposure to direct UV light.

  • Severe renal or hepatic failure.

• Key Drug Interactions:

  • Digoxin: Increases risk of digoxin toxicity.

  • Antidiarrheals, Antacids, Dairy Products, Iron, and Zinc: Chelates tetracycline and drastically decreases drug absorption.

  • Oral Contraceptives: Decreases contraceptive efficacy.

• Nursing Considerations:

  • Monitor liver function tests, skin reactions, and signs of superinfection.

  • Avoid co-administration with dairy or metal cations.

• Patient Teaching Points:

  • Take on an empty stomach $1\,\text{hour}$ before or $2\,\text{hours}$ after meals.

  • Do not take immediately before lying down/bedtime (prevents esophageal ulceration).

  • Report suspected pregnancy, jaundice, abdominal pain, or extreme fatigue immediately.

• Developmental Considerations:

  • Pediatrics: Strictly contraindicated under $8\,\text{years}$ of age due to permanent enamel discoloration and bone growth inhibition.

  • Pregnancy: Strictly contraindicated.

  • Older Adults: Dose adjustments required based on renal clearance.

Macrolides

• Prototype Drug: Azithromycin

• Indications: First-line choice for Legionnaires' disease, pertussis (whooping cough), acute diphtheria; alternative therapy for infections in patients with penicillin allergies; newborn ophthalmic prophylaxis.

• Mechanism of Action (MOA): Alters ribosomal protein synthesis; bacteriostatic or bactericidal depending on dosage.

• Routes of Administration: PO, IV, Ophthalmic, Topical.

• Adverse Effects:

  • GI manifestations (N/V, severe diarrhea, abdominal pain).

  • Cardiac dysrhythmias associated with QT interval prolongation.

  • Ototoxicity (reversible or irreversible hearing loss, vertigo, tinnitus).

  • C. diff superinfections.

• Contraindications:

  • History of prolonged QT syndrome.

  • Uncorrected hypokalemia or hypomagnesemia.

  • Caution: Existing GI or hepatic disorders.

• Key Drug Interactions:

  • Chloramphenicol and Clindamycin: Azithromycin decreases effective blood levels of these antibiotics.

  • Digoxin, Warfarin, and Theophylline: Azithromycin increases serum concentrations of these medications, elevating toxicity risks.

• Nursing Considerations:

  • Monitor for ototoxicity, QT interval prolongation, liver function abnormalities, and severe GI symptoms.

• Patient Teaching Points:

  • Take with food if GI distress occurs.

  • Promptly report palpitations, fainting spells, watery/bloody diarrhea, white mouth patches, hearing changes, vertigo, or tinnitus.

• Developmental Considerations:

  • Older Adults: Significantly higher risk for fatal QT prolongation and dysrhythmias.

Antivirals

• Prototype Drug: Acyclovir

• Indications: Herpes simplex virus (HSV), Cytomegalovirus (CMV), Varicella-Zoster virus (VZV), and opportunistic viral infections in immunocompromised individuals.

• Mechanism of Action (MOA): Inhibits viral DNA polymerase and DNA replication.

• Routes of Administration: PO, Buccal, Topical, IV.

• Adverse Effects:

  • Topical: Localized burning, stinging, or itching.

  • Oral: GI distress, headache, vertigo.

  • IV: Severe renal toxicity (crystalluria), CNS toxicity (confusion, tremors), and site thrombophlebitis.

• Contraindications:

  • Buccal Route: Known hypersensitivity to milk protein concentrate.

  • Caution: Renal insufficiency, neurological disorders, dehydration.

• Key Drug Interactions:

  • Probenecid: Increases serum acyclovir concentration.

  • Zidovudine: Increases neurotoxicity and profound lethargy.

  • Nephrotoxic Drugs: Synergistic increase in renal damage risk.

• Nursing Considerations:

  • Monitor BUN and serum creatinine levels.

  • Infuse IV formulations slowly over at least $1\,\text{hour}$ and maintain vigorous patient hydration during infusion and for $2\,\text{hours}$ post-infusion to prevent renal tubular crystallization.

  • Wear gloves when applying topical formulations.

• Patient Teaching Points:

  • Avoid contact with eyes when applying topically.

  • Avoid OTC creams or lotions on herpes lesions without provider approval.

  • Females with HSV-2 require annual Pap smears due to increased risk of cervical dysplasia.

  • Use barrier contraceptives (condoms) to lower transmission risks.

  • Report persistent neurological symptoms, IV site pain, or severe skin changes.

• Developmental Considerations:

  • Pediatrics: Maintain intravenous fluid hydration to mitigate renal crystal deposition.

  • Older Adults: Higher risk for neurotoxicity and nephrotoxicity; requires renal-adjusted dosing schedules.

Antifungals

• Prototype Drug: Nystatin

• Indications: Treatment of localized and mucocutaneous Candidiasis (oral thrush, cutaneous infections).

• Mechanism of Action (MOA): Binds to sterols in fungal cell membranes, altering membrane permeability; fungicidal.

• Routes of Administration: Oral (PO suspension/swish), Topical.

• Adverse Effects: GI distress (nausea, vomiting, diarrhea), localized skin irritation.

• Contraindications: Known hypersensitivity.

• Nursing Considerations & Patient Teaching:

  • Oral Suspension: Shake thoroughly before administration. Swish the liquid around the mouth for as long as possible (coating all mucosal surfaces) before swallowing or spitting out as specifically ordered.

  • Topical Application: Cleanse and dry the target skin area completely before applying.

  • Post-Administration Guidance: Do not eat or drink for $30\,\text{minutes}$ following oral swish-and-swallow/spit administration to ensure sufficient drug contact time with oral mucosa.

Immunology and Vaccines

• Immunity Principles:

  • Immunity: A state of relative host protection and resistance to a disease that develops following exposure to a target pathogen or antigen.

  • Active Immunity: Immune system actively produces an adaptive response.

  • Humoral Response: B cells recognize pathogens and secrete specific antibodies.

  • Cell-Mediated Response: T cells target and destroy infected host cells.

  • Passive Immunity: Pre-formed antibodies are transferred into a host, offering immediate but temporary protection.

  • Maternal Antibodies: Transferred via placenta or breast milk.

  • Monoclonal Antibodies: Exogenous therapeutic antibody infusions.

• Vaccine Mechanism: Vaccines train the host immune system by exposing it to altered antigens $\rightarrow$ triggers B cells to produce antibodies $\rightarrow$ generates long-lasting memory cells.

• Vaccine Categories:

  • Live Attenuated: Contains a weakened form of the live microbe.

  • Inactivated: Uses a fully killed version of the germ.

  • Subunit / Recombinant: Contains specific isolated antigenic pieces of the germ.

  • Toxoid: Uses an inactivated bacterial toxin.

  • mRNA: Directs host cells to produce a viral protein to trigger an immune response.

• Vaccine Formulation Components:

  • Antigen: Specific disease-target component.

  • Adjuvant: Chemical enhancer that boosts the overall immune response.

  • Stabilizers: Compounds that preserve vaccine potency during storage.

  • Preservatives: Chemical additives preventing microbial contamination.

• Benefits of Vaccination:

  • Individual disease prevention.

  • Herd Immunity: Community-level protection achieved when a high percentage of immunized individuals prevents pathogen transmission, thereby shielding unimmunized or vulnerable populations.

  • Global eradication and containment of infectious agents.

• General Vaccine Administration and Precautions:

  • Administration Routes: Subcutaneous (SubQ), Intranasal (LAIV), Intramuscular (IM).

  • General Contraindications:

  • Delay administration in patients who have recently received exogenous immunoglobulins or blood products.

  • Use extreme caution in children with a history of febrile convulsions or cerebral injury.

  • Known severe allergic reaction (anaphylaxis) to any vaccine component (e.g., egg protein present in certain influenza formulations).

  • Specific Live Vaccine Contraindications:

  • Primary immune deficiency states, severe immunosuppressive drug therapy, and pregnancy.

  • Common Adverse Effects: Local site inflammation (pain, erythema, nodule); systemic inflammatory reactions (low-grade fever, malaise, chills, irritability); hypersensitivity; rarely, seizures.

• Comparison of Common Vaccines:

  • Influenza A & B:

  • Types: IIV (Inactivated Influenza Vaccine) or LAIV (Live Attenuated Influenza Vaccine).

  • Routes: IM (IIV); Intranasal spray (LAIV).

  • Schedule: Annual administration; ideally completed by the end of October.

  • Pregnancy / Immunocompromised: IIV is recommended and safe; LAIV is strictly contraindicated.

  • MMR (Measles, Mumps, Rubella):

  • Type: Live attenuated.

  • Route: Subcutaneous.

  • Schedule: $2$ doses; First dose at $12\text{--}15\,\text{months}$, second dose at $4\text{--}6\,\text{years}$.

  • Pregnancy / Immunocompromised: Contraindicated in pregnancy and severe immunosuppression.

  • Varicella (Chickenpox):

  • Type: Live attenuated.

  • Route: Subcutaneous.

  • Schedule: $2$ doses; First dose at $>12\,\text{months}$, second dose $4\text{--}8\,\text{weeks}$ later.

  • Pregnancy / Immunocompromised: Contraindicated in pregnancy and severe immunosuppression.

Immune Sera

• Passive Immunity via Immune Sera:

  • Provides pre-formed antibodies directed against specific toxins, venoms, or pathogens.

  • Indicated for post-exposure prophylaxis in non-immunized or immunocompromised individuals to rapidly lessen disease severity.

• Contraindications: History of severe adverse reactions to immune sera formulations. Use caution in patients with coagulation disorders or severe thrombocytopenia.

• Adverse Effects: Systemic immune response (fever, chills, N/V, rash); local administration site tenderness and muscle stiffness; hypersensitivity (dyspnea, chest tightness, severe hypotension).

• Specific Agent Profile: Rabies Immune Globulin (RIG):

  • Indication: Immediate passive protection against rabies in non-immunized individuals following suspected or confirmed rabies exposure; given concurrently with the active rabies vaccine.

  • Administration Route: Infiltrate the calculated dose thoroughly into and around the wound site; any remaining volume is injected IM at a distant anatomical location.

  • Dosing: $20\,\text{IU/kg}$ as a single dose.

  • Administration Warning: Never mix Rabies Immune Globulin and the active rabies vaccine in the same syringe, nor inject them into the same anatomical site.

  • Pregnancy & Immunocompromised Status: Neither condition contraindicates RIG administration.

NCLEX Practice Questions & Discussion

• Question 1: The nurse is caring for an older adult client who is starting levofloxacin. Which finding would be most important for the nurse to monitor for during treatment?

  • A. Discoloration of the teeth

  • B. Pain or swelling near the Achilles tendon

  • C. Yellowing of the skin

  • D. Difficulty swallowing pills

  • Answer: B

  • Rationale: Fluoroquinolones carry a risk of tendonitis and tendon rupture, particularly involving the Achilles tendon. Older adults and those taking concurrent corticosteroids are at the highest risk.

• Question 2: The nurse is preparing to administer the first dose of amoxicillin to a client. Before administering the medication, which question is most important for the nurse to ask?

  • A. "Have you eaten anything today?"

  • B. "Are you allergic to penicillin?"

  • C. "Do you have a history of high blood pressure?"

  • D. "Have you had any recent surgeries?"

  • Answer: B

  • Rationale: Assessing for hypersensitivity/allergy history is the highest priority safety intervention prior to administering any penicillin derivative.

• Question 3: The nurse is teaching a parent about a new prescription for a tetracycline antibiotic for their 6-year-old child. Which statement by the parent indicates a need for further teaching?

  • A. "I will give this medication with a full glass of water."

  • B. "It's fine to give this medication with a glass of milk."

  • C. "This medication may cause my child's teeth to look discolored."

  • D. "I will call the provider if my child develops a rash."

  • Answer: B

  • Rationale: Dairy products contain calcium, which chelates tetracyclines and severely impairs drug absorption. Furthermore, tetracyclines are contraindicated in children under $8\,\text{years}$ of age due to risk of permanent tooth discoloration.

• Question 4: The nurse is caring for four clients receiving IV antibiotics. Which client should the nurse check on first?

  • A. The patient receiving amoxicillin who has a stable rash present for several days

  • B. The patient receiving azithromycin who is due for a dose in one hour

  • C. The patient receiving levofloxacin who reports mild nausea

  • D. The patient receiving gentamicin who reports new ringing in the ears

  • Answer: D

  • Rationale: New onset ringing in the ears (tinnitus) indicates aminoglycoside-induced ototoxicity. This requires immediate intervention to halt potential permanent auditory nerve damage.

• Question 5: A nurse is preparing to administer a live attenuated vaccine (such as MMR) to a client. Which question is most important for the nurse to ask before giving this vaccine?

  • A. "Have you had any caffeine today?"

  • B. "Are you pregnant, or could you be pregnant?"

  • C. "Do you have a history of seasonal allergies?"

  • D. "Have you traveled internationally in the last year?"

  • Answer: B

  • Rationale: Live attenuated vaccines are strictly contraindicated during pregnancy due to the theoretical risk of viral transmission and teratogenic effects on the fetus.